Michael Song

Safety in moderate‐to‐severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti‐tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials

M. Lebwohl, M. Gooderham, L. Puig, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Work/study productivity gain and associated indirect cost savings with guselkumab compared with adalimumab in moderate-to-severe psoriasis: results from the VOYAGE 1 study

A. Armstrong, E. Muser, M. Song, 2020, The Journal of dermatological treatment.

THU0419 Integrated Safety of Ustekinumab in Psoriatic Arthritis: 2 Year Follow-Up from the Psoriatic Arthritis Clinical Development Program

I. McInnes, C. Ritchlin, A. Kavanaugh, 2015 .

The safety of ustekinumab treatment in patients with moderate‐to‐severe psoriasis and latent tuberculosis infection

M. Song, Y. Wasfi, Y. Shen, 2012, The British journal of dermatology.

Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label CADMUS Jr study

A. Paller, M. Song, L. Eichenfield, 2020, The British journal of dermatology.